Enveric Biosciences

  Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Comprehensive net loss for the year was $48.8 million, including $36.3 million in net non-cash expenses, with a basic and diluted loss per share of $2.07...

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second...